WILL G. RYAN, M.D.; THEODORE B. SCHWARTZ, M.D.; E. W. FORDHAM, M.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Slightly more than a decade has passed since we reported the effects of mithramycin on Paget's disease of bone (1). During that interval we have used mithramycin in the treatment of over 150 patients with the malady and have found it uniformly effective in suppression of both objective and subjective signs of activity of the disease (2). Despite these results the drug has not come into widespread use for this disorder largely because of concern about its serious side effects. Because of the effectiveness and more benign nature of the diphosphonates (sodium etidronate) and calcitonins (synthetic salmon
RYAN WG, SCHWARTZ TB, FORDHAM EW. Mithramycin and Long Remission of Paget's Disease of Bone. Ann Intern Med. ;92:129–130. doi: 10.7326/0003-4819-92-1-129_2
Download citation file:
Published: Ann Intern Med. 1980;92(1):129-130.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use